Health Care·Biotechnology·$6.4B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.54 | N/A | +4.93% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.54 | N/A | +4.93% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed optimism about ongoing projects and their potential impact. However, they did not offer specific guidance for the upcoming quarters.
Management highlighted progress in their clinical trials.
They emphasized their commitment to advancing their pipeline.
No specific guidance was provided for future quarters.
Protagonist Therapeutics reported a narrower-than-expected loss per share, which contributed to a slight increase in stock price. Investors reacted positively to the management's comments on clinical trial progress, despite the lack of revenue data and future guidance. The stock's modest gain reflects cautious optimism among investors.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SUNCOR ENERGY INC NE
May 3, 2021